| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -9,297 | -5,938 |
| Depreciation expense | 3 | 2 |
| Stock-based compensation expense | 726 | 261 |
| Change in fair value of warrant liability | 0 | 0 |
| Change in operating lease right-of-use assets | 36 | 23 |
| Prepaid expenses and other current assets | -265 | -133 |
| Accounts payable | 391 | 371 |
| Accrued expenses | 697 | 269 |
| Operating lease liabilities | -36 | -23 |
| Cash used in operating activities | -7,215 | -4,902 |
| Proceeds from issuance of common stock-Through Financing | 5,000 | 5,000 |
| Proceeds from issuance of common stock-At The Market Offering | 2,560 | 941 |
| Proceeds from warrant exercise | 0 | - |
| Payment for fractional shares in connection with reverse stock split | 1 | 1 |
| Payment of stock issuance costs | 1,317 | 944 |
| Cash provided by financing activities | 6,242 | 4,996 |
| Net (decrease) increase in cash and cash equivalents | -973 | 94 |
| Cash and cash equivalents at beginning of period | 5,028 | - |
| Cash and cash equivalents at end of period | 4,055 | - |
GRI Bio, Inc. (GRI)
GRI Bio, Inc. (GRI)